Post hoc analysis of SELECT-PsA 2 in 195 patients with psoriatic arthritis exposed to one prior TNF inhibitor: upadacitinib 15 mg once daily vs placebo gave higher week-24 ACR20 (57.8% vs 21.9%), maintained to week 152, with no new safety signals.
Secondary analysisn = 195
Coates et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2